Meet Our New Fatty Liver Disease Program Director!
Meet the Director
Global Liver Institute is excited to announce the appointment of Dr. Sharon Jaycox as the new Fatty Liver Disease Program Director. Dr. Jaycox joined GLI at the end of January and brings extensive experience in public health and clinical research. Her commitment to advocacy and support for patients and caregivers is central to her mission. Collaboration with our partners is essential for the success of the Fatty Liver Disease Program, and Dr. Jaycox’s expertise and dedication will undoubtedly help propel GLI toward achieving its goals.
Global Fatty Liver Day is on June 12!
Mark your calendars for Global Fatty Liver Day on June 12, 2025! Join us in raising awareness and driving action to combat fatty liver disease and its more advanced forms, worldwide. Partner with us to host events, share resources, and make a lasting impact on liver health.
GLP-1s & Your Liver
The latest episode of Is Your Liver Healthy? brought on Dr. Janese Laster, gastroenterologist and founder of Total Gut Theory Health, and Joe Nadglowski, CEO of the Obesity Action Coalition, to discuss the science and policy behind the blockbuster class of anti-obesity medications and implications for liver health.
🎧 Listen to the episode on YouTube, Apple Podcasts, Spotify, or wherever you get your podcasts.
Looking Ahead to the Future of MASH Management
GLI’s Vice President of Liver Health, Jeff McIntyre, is joined by Dr. Mazen Nourredin and Dr. Juan Pablo Arab in a panel for HCP Live to discuss resmetirom’s impact on clinical practice and patient care and how it continues to evolve, one year after its launch. The approval addresses a significant unmet need, as previous MASH management strategies primarily relied on lifestyle modifications, which often proved insufficient.
Emerging Insights
Is Fatty Liver Developing into New Types Of Diabetes?
Metabolic Dysfunction-Associated Liver Disease (MASLD) is a combination of fatty liver disease with metabolic indications, meaning those anomalies that fall under metabolic syndromes such as diabetes and cardiovascular disorders. Like other cultural groups, the Indian population is seeing a rise in MASLD, and those in the medical and scientific communities are concerned that liver disease will become the “new diabetes”. In a recent interview, Dr. Prathiba Setty, Medical Gastroenterology Consultant at Manipal Hospital in Jayanag, discusses how we can prevent fatty liver from developing into new types of diabetes.
The EMA qualifies as an AI tool to help in the diagnosis of MASH
The European Medicines Agencies (EMA) Human Medicine Committee (CHMP) has issued its first Qualification Opinion (QO) for a tool, named AIM-NASH. This tool will identify MASH severity and aim to reduce variability in scoring liver inflammation and fibrosis in clinical trials. AIM-NASH will be employed in clinical trials to improve the reliability and efficacy of clinical measures.
Ireland becomes the first EU country to introduce health warnings on alcohol labels starting May 2026
Alcohol is a risk factor for liver disease as well as a number of other medical conditions including 7 types of cancer and cardiovascular disease. An annual survey in Ireland found 7% of the responders believed low alcohol consumption was safe during pregnancy, and an alarming 80% were unaware of the other associated risk factors. While Alcohol product labeling is not done in the EU, Irish health officials believe health information could increase awareness and
⬇️ Education Resources Available ⬇️
GLI is proud to offer a range of continuing education programs to support healthcare providers in expanding their knowledge and skills in MASLD and MASH. These programs provide valuable CE credits and are available until June 2025.
Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes
Through a partnership with the Global Learning Collaborative, GLI now offers this continuing education course on ReachMD. This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri, Robert Eckel, and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
In collaboration with the Medical Learning Institute, GLI presents an interactive course to Build Your Own Case Study. Healthcare providers in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD and MASH and its associated risk factors, as well as feel confident about how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Upcoming Events
- April 7, 2025: SOLDA SIG webinar: Models of Care in Prevention of Vertical Transmission of HBV in Africa
- April 19, 2025: World Liver Day
- April 25, 2025: SOLDA Webinar: World Liver Day
- May 2, 2025 : Beyond the Biopsy: Breaking Barriers in Diagnosis, San Diego, CA
- May 7- 10, 2025: EASL Congress, Amsterdam, The Netherlands